Profile data is unavailable for this security.
About the company
Sutro Biopharma, Inc. is a clinical-stage oncology company. The Company is engaged in developing site-specific and novel-format antibody drug conjugates (ADCs) enabled by its integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. The Company’s advanced product candidate is STRO-002 (luveltamab tazevibulin, or luvelta), an ADC directed against folate receptor-alpha (FolRa), for patients with FolRa-expressing cancers, including ovarian cancer. In addition, it uses luvelta to treat pediatric patients with relapsed/refractory CBFA2T3-GLIS2 and acute myeloid leukemia. It also has two preclinical product candidates, STRO-003 and STRO-004. These product candidates are single homogeneous ADCs directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1), and tissue factor (TF), each of which is being developed for the treatment of solid tumors.
- Revenue in USD (TTM)160.96m
- Net income in USD-123.95m
- Incorporated2003
- Employees306.00
- LocationSutro Biopharma Inc111 Oyster Point Blvd.SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 392-8412
- Fax+1 (302) 655-5049
- Websitehttps://www.sutrobio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Editas Medicine Inc | 61.76m | -210.57m | 195.64m | 265.00 | -- | 1.11 | -- | 3.17 | -2.56 | -2.56 | 0.752 | 2.13 | 0.1484 | -- | 48.48 | 233,049.10 | -50.61 | -29.85 | -60.06 | -33.19 | -- | -- | -340.96 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
| Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 197.27m | 145.00 | -- | 1.32 | -- | 2.74 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Acrivon Therapeutics Inc | 0.00 | -76.98m | 199.46m | 58.00 | -- | 1.02 | -- | -- | -2.70 | -2.70 | 0.00 | 6.32 | 0.00 | -- | -- | 0.00 | -42.09 | -- | -45.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| Climb Bio Inc | 0.00 | -69.12m | 201.18m | 9.00 | -- | 0.9218 | -- | -- | -2.13 | -2.13 | 0.00 | 3.25 | 0.00 | -- | -- | 0.00 | -41.28 | -- | -42.07 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| MacroGenics Inc | 141.33m | -97.62m | 201.47m | 339.00 | -- | 1.68 | -- | 1.43 | -1.57 | -1.57 | 2.26 | 1.91 | 0.4676 | 3.24 | 8.30 | 416,899.70 | -32.30 | -37.76 | -39.53 | -45.53 | 95.07 | -- | -69.07 | -133.96 | 3.69 | -93.94 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| XBiotech Inc | 0.00 | -32.66m | 201.67m | 92.00 | -- | 1.05 | -- | -- | -1.07 | -1.07 | 0.00 | 6.30 | 0.00 | -- | -- | 0.00 | -14.86 | 31.88 | -15.62 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0495 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Perspective Therapeutics Inc | -3.68m | -53.78m | 202.28m | 116.00 | -- | 0.6171 | -- | -- | -1.24 | -1.59 | -0.069 | 4.86 | -0.0147 | -- | -- | -31,741.38 | -21.44 | -- | -23.11 | -- | -- | -- | -- | -- | -- | -- | 0.0051 | -- | -- | -- | -- | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -38.70m | 203.76m | 19.00 | -- | 1.35 | -- | -- | -4.69 | -4.69 | 0.00 | 12.36 | 0.00 | -- | -- | 0.00 | -38.61 | -86.84 | -49.21 | -130.46 | -- | -- | -- | -769.76 | -- | -- | 0.00 | -- | -- | -- | -5.33 | -- | -- | -- |
| Lexeo Therapeutics Inc | 0.00 | -86.60m | 204.98m | 58.00 | -- | 1.47 | -- | -- | -2.89 | -2.89 | 0.00 | 4.21 | 0.00 | -- | -- | 0.00 | -75.77 | -- | -96.90 | -- | -- | -- | -- | -- | -- | -- | 0.0107 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Sutro Biopharma Inc | 160.96m | -123.95m | 207.37m | 306.00 | -- | 1.87 | -- | 1.29 | -1.62 | -1.62 | 2.25 | 1.35 | 0.3643 | -- | 13.83 | 532,963.60 | -28.06 | -25.48 | -36.53 | -29.75 | -- | -- | -77.01 | -113.71 | -- | -- | 0.00 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Tscan Therapeutics Inc | 9.36m | -111.30m | 208.72m | 188.00 | -- | 0.9176 | -- | 22.29 | -1.05 | -1.05 | 0.0887 | 4.29 | 0.0293 | -- | -- | 60,792.21 | -34.81 | -- | -38.54 | -- | -- | -- | -1,188.88 | -- | -- | -- | 0.118 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -102.44m | 208.96m | 88.00 | -- | 1.22 | -- | -- | -3.04 | -3.04 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -51.66 | -49.99 | -57.25 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0081 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Trevi Therapeutics Inc | 0.00 | -44.32m | 209.84m | 25.00 | -- | 3.49 | -- | -- | -0.4412 | -0.4412 | 0.00 | 0.7815 | 0.00 | -- | -- | 0.00 | -53.78 | -47.39 | -58.89 | -54.41 | -- | -- | -- | -- | -- | -- | 0.001 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Onkure Therapeutics Inc | 0.00 | -41.03m | 213.30m | 8.00 | -- | 0.7223 | -- | -- | -12.25 | -12.25 | 0.00 | 22.14 | 0.00 | -- | -- | 0.00 | -39.45 | -- | -42.92 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Amarin Corporation plc (ADR) | 241.02m | -39.35m | 215.91m | 275.00 | -- | 0.4063 | -- | 0.8958 | -0.0959 | -0.0959 | 0.5876 | 1.29 | 0.3032 | 0.4387 | 2.05 | 876,440.00 | -4.95 | -4.48 | -7.02 | -6.54 | 56.46 | 75.70 | -16.32 | -8.59 | 2.11 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
Data as of Nov 22 2024. Currency figures normalised to Sutro Biopharma Inc's reporting currency: US Dollar USD
39.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Suvretta Capital Management LLCas of 30 Sep 2024 | 7.19m | 8.77% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 5.75m | 7.01% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 4.13m | 5.04% |
| Point72 Asset Management LPas of 30 Sep 2024 | 3.00m | 3.66% |
| Adage Capital Management LPas of 30 Sep 2024 | 2.25m | 2.75% |
| Citadel Advisors LLCas of 30 Sep 2024 | 2.09m | 2.55% |
| Kynam Capital Management LPas of 30 Sep 2024 | 2.07m | 2.52% |
| Millennium Management LLCas of 30 Sep 2024 | 2.03m | 2.48% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.86m | 2.27% |
| Eversept Partners LPas of 30 Sep 2024 | 1.84m | 2.25% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
